In light of the recent discovery that CDC25 is the therapeutic target of choice in triple-negative breast cancers, namely those that are negative for estrogen-, progesterone- and HER2-receptor expression and that are unresponsive to standard therapy22, we set out to develop novel CDC25 inhibitors. The gene discussed is CDC25C; the disease is triple-negative breast carcinoma.